Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Stopped Sufficient evidence of efficacy not met. Discontinuation not based on any safety concerns.
Conditions
Interventions
- DRUG: Donepezil hydrochloride (Aricept)
Sponsor
Eisai Inc.
Collaborators